Read by QxMD icon Read


shared collection
9 papers 25 to 100 followers Questioning Medicine upcoming podcast #FOAMed #MedQuestioning
By Joe Weatherly FM/Hospitalist-CoFounder of QuestioningMedicine and PCRAP contributor.
Sander M Botter, Dario Neri, Bruno Fuchs
Although osteosarcoma (OS) is a rare malignancy, it is ranked among the leading causes of cancer-related death in the pediatric age group. The cancer's low prevalence and its large tumor heterogeneity make it difficult to obtain meaningful progress in patient survival. In this review we present an overview of current clinical trials which largely focus on stimulation of the immune system or rely on the inhibition of kinases such as Src and mTOR. The potential efficacy of tumor-targeted TNFalpha is discussed, as well as the importance of preclinical validation of new targets...
June 2014: Current Opinion in Pharmacology
Jing Wang, Qiong Shi, Tai-Xian Yuan, Qi-Lin Song, Yan Zhang, Qiang Wei, Lan Zhou, Jinyong Luo, Guowei Zuo, Min Tang, Tong-Chuan He, Yaguang Weng
The aim of this study is to determine the value of matrix metalloproteinase 9 (MMP-9) in diagnosis of osteosarcoma (OS). A systematic review and meta-analysis was conducted using MEDLINE, Embase, ISI Web of Knowledge, the Cochrane Library, Scopus, BioMed Central, ScienceDirect, China Biomedical literature Database (CBM) and China National Knowledge Internet (CNKI) from inception through Aug 29, 2013. Articles written in English or Chinese that investigated the accuracy of MMP-9 for the diagnosis of OS were included...
June 10, 2014: Clinica Chimica Acta; International Journal of Clinical Chemistry
Anja Luetke, Paul A Meyers, Ian Lewis, Heribert Juergens
Long-term outcome for patients with high-grade osteosarcoma has improved with the addition of systemic chemotherapy, but subsequent progress has been less marked. Modern, multiagent, dose-intensive chemotherapy in conjunction with surgery achieves a 5-year event-free survival of 60-70% in extremity localized, non-metastatic disease. A major, as yet unsolved, problem is the poor prognosis for metastatic relapse or recurrence, and for patients with axial disease. This article reviews the current state of the art of systemic osteosarcoma therapy by focusing on the experiences of cooperative osteosarcoma groups...
May 2014: Cancer Treatment Reviews
Miroslava Krzyzankova, Silvia Chovanova, Petr Chlapek, Matej Radsetoulal, Jakub Neradil, Karel Zitterbart, Jaroslav Sterba, Renata Veselska
The induced differentiation of tumor cells into mature phenotypes is a promising strategy in cancer therapy. In this study, the effects of combined treatment with all-trans retinoic acid (ATRA) and lipoxygenase/cyclooxygenase inhibitors were examined in two osteosarcoma cell lines, Saos-2 and OSA-01. Caffeic acid and celecoxib were used as inhibitors of 5-lipoxygenase and of cyclooxygenase-2, respectively. Changes in the cell proliferation, matrix mineralization, and occurrence of differentiation markers were evaluated in treated cell populations at intervals...
August 2014: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
Chand Khanna, Timothy M Fan, Richard Gorlick, Lee J Helman, Eugenie S Kleinerman, Peter C Adamson, Peter J Houghton, William D Tap, Danny R Welch, Patricia S Steeg, Glenn Merlino, Poul H B Sorensen, Paul Meltzer, David G Kirsch, Katherine A Janeway, Brenda Weigel, Lor Randall, Stephen J Withrow, Melissa Paoloni, Rosandra Kaplan, Beverly A Teicher, Nita L Seibel, Malcolm Smith, Aykut Uren, Shreyaskumar R Patel, Jeffrey Trent, Sharon A Savage, Lisa Mirabello, Denise Reinke, Donald A Barkaukas, Mark Krailo, Mark Bernstein
Despite successful primary tumor treatment, the development of pulmonary metastasis continues to be the most common cause of mortality in patients with osteosarcoma. A conventional drug development path requiring drugs to induce regression of established lesions has not led to improvements for patients with osteosarcoma in more than 30 years. On the basis of our growing understanding of metastasis biology, it is now reasonable and essential that we focus on developing therapeutics that target metastatic progression...
August 15, 2014: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Patrice Penfornis, David Z Cai, Michael R Harris, Ryan Walker, David Licini, Joseph D A Fernandes, Griffin Orr, Tejaswi Koganti, Chindo Hicks, Spandana Induru, Mark S Meyer, Rama Khokha, Jennifer Barr, Radhika R Pochampally
Overall prognosis for osteosarcoma (OS) is poor despite aggressive treatment options. Limited access to primary tumors, technical challenges in processing OS tissues, and the lack of well-characterized primary cell cultures has hindered our ability to fully understand the properties of OS tumor initiation and progression. In this study, we have isolated and characterized cell cultures derived from four central high-grade human OS samples. Furthermore, we used the cell cultures to study the role of CD49f in OS progression...
August 2014: Cancer Medicine
Xuanwei Wang, Jingyu Du, Pengcheng Gu, Rilong Jin, Xiangjin Lin
The prognosis of patients with osteosarcoma with distant metastasis and local recurrence remains poor. Increased expression of polymeric immunoglobulin receptor (pIgR) in tumor tissue has been detected in various types of cancer. However, the clinical significance of pIgR in osteosarcoma has yet to be elucidated. The present study aimed to investigate the prognostic value of pIgR in patients with osteosarcoma following surgical resection. pIgR expression was assessed using quantitative polymerase chain reaction analysis in cryopreserved osteosarcoma tissues from 22 patients, as well as using immunohistochemistry in paraffin-embedded osteosarcoma tissues from 136 patients...
June 2014: Molecular Medicine Reports
Giulia Bernardini, Marcella Laschi, Tommaso Serchi, Adriano Spreafico, Maurizio Botta, Silvia Schenone, Simona Arena, Michela Geminiani, Andrea Scaloni, Giulia Collodel, Maurizio Orlandini, Neri Niccolai, Annalisa Santucci
Osteosarcoma (OS) is a highly malignant bone tumour, affecting mainly children and young adults between 10 and 20 years of age. It represents the most frequent primitive malignant tumour of the skeletal system and is characterized by an extremely aggressive clinical course, with rapid development of lung metastases. In the last few years, targeting Src in the treatment of OS has become one of the major challenges in the development of new drugs, since an elevated Src kinase activity has been associated with the development and the maintenance of the OS malignant phenotype...
June 2014: Molecular BioSystems
Bingpeng Chen, Jingjing Liu, Dankai Wu, Yanguo Qin, Chuangang Peng, Chen Li, Jincheng Wang
NIN1/RPN12 binding protein 1 homolog (Saccharomyces cerevisiae) (NOB1) encodes a chaperone protein that joins the 20S proteasome with the 19S regulatory particle in the nucleus and facilitates the biogenesis of the 26S proteasome, which plays a role in maintaining cellular homeostasis by controlling protein degradation. In order to investigate the role of NOB1 in osteosarcoma, NOB1 protein expression in human osteosarcoma cell lines was assessed using western blot analysis. Lentivirus-mediated short hairpin RNA was employed to knock down NOB1, and the effects of NOB1 silencing on cell growth were assessed using MTT, colony formation and cell cycle assays...
June 2014: Molecular Medicine Reports
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"